Mustang Bio has entered a research collaboration deal with Beth Israel Deaconess Medical Center and a licensing agreement with Harvard University to develop CRISPR-Cas9-enhanced chimeric antigen receptor-engineered T-cell therapies for cancer. No financial details were disclosed.
Partnerships to advance development of CRISPR-Cas9 CAR-T therapies
Sign up for SNMMI SmartBrief
Nuclear medicine and molecular imaging news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.